Does magnesium deficiency impair insulin signaling and raise fasting glucose and triglycerides?

Magnesium status is biologically relevant to insulin action and glucose handling, but the clinical effects of repletion appear most evident in people with documented hypomagnesemia and metabolic risk—not universally across all populations.

Mechanistic evidence

• Magnesium is required for MgATP, the functional substrate for ATP-dependent phosphate transfer. Low magnesium can therefore impair glycolytic phosphorylation, including hexokinase- and phosphofructokinase-dependent steps, and compromise cellular glucose flux.
• In hypomagnesemic rats, insulin-receptor β-subunit autophosphorylation and receptor tyrosine-kinase activity fell by approximately 50% despite unchanged insulin binding. In adipocytes, magnesium depletion reduced insulin-stimulated Akt activation, GLUT4 translocation, and glucose uptake by about 50%.
• These findings indicate effects both at the receptor and downstream insulin-signaling levels; receptor phosphorylation may remain intact in some cell types while post-receptor signaling is impaired.

Clinical metabolic findings

• In a double-blind trial of adults with prediabetes and hypomagnesemia, 4 months of magnesium chloride (382 mg elemental magnesium/day) lowered fasting glucose versus placebo (86.9 vs 98.3 mg/dL; P=0.004) and improved HOMA-IR.
• Low serum magnesium is also associated prospectively with increased type 2 diabetes incidence, although this association does not prove causality.
• For triglycerides, a 16-week placebo-controlled trial in metabolic syndrome with hypomagnesemia reported a 61.2 ± 24 mg/dL greater fasting-triglyceride reduction with magnesium chloride (P=0.003). Other trials, including magnesium oxide in prediabetes, found no triglyceride or fasting-glucose benefit.

Bottom line

• Magnesium deficiency is supported as a contributor to impaired insulin signaling, MgATP-dependent glucose metabolism, and higher fasting glucose—particularly in prediabetes with confirmed hypomagnesemia. A contribution to elevated fasting triglycerides is plausible but less firmly established because trial results are inconsistent.